

## **Curis to Release Third Quarter 2015 Financial Results and Hold Conference Call on November 9, 2015**

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its third quarter 2015 financial results on Monday, November 9, 2015, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST to review: (i) its proprietary clinical development programs, including CUDC-907, (ii) programs under its collaboration with Aurigene, including CA-170, an oral small molecule antagonist of PD-L1/VISTA, and (iii) its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the three- and nine-month periods ended September 30, 2015.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 66760275. The conference call can also be accessed on the Curis website at [www.curis.com](http://www.curis.com) in the Investors section.

### **About Curis, Inc.**

Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of PD-1/ VISTA checkpoint molecules and IRAK4 kinase. Curis is also party to a collaboration agreement with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, which is approved for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Senior Vice President, Corporate Strategy

and Investor Relations

Curis, Inc.

617-503-6605

[mmohindru@curis.com](mailto:mmohindru@curis.com)

Media Contact:

David Schull

Russo Partners

212-845-4271

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

---

<https://investors.curis.com/Curis-to-Release-Third-Quarter-2015-Financial-Results-and-Hold-Conference-Call-on-November-9-2015>